Welcome to Rejuvenation Science®!

 Questions? Please call us at
1-888-737-3588 TOLL FREE

A six year clinical study of therapy of cardiomyopathy with Coenzyme Q10

Langsjoen PH; Langsjoen PH; Folkers K
Department of Medicine, Scott & White Clinic, Temple TX.
Int J Tissue React (SWITZERLAND) 1990, 12(3) P169-71,

One hundred and forty-three cases of chronic, stable, non-secondary, non hypertrophic cardiomyopathy, 98% of whom were in NYHA Classes III and IV, were given 100 mg of coenzyme Q10 orally in addition to their conventional medical programme in an open-label long-term study. Blood CoQ10 levels, clinical status, myocardial function and survival have been recorded now for almost 6 years. Mean control/CoQ10 levels of 0.85 micrograms/ml rose to 2 micrograms/ml in 3 months and remained stable at that level. Mean ejection fraction of 44% measured by systolic time interval analysis rose to 60% within 6 months and stabilized at that level with 84% of patients showing statically significant improvement. Eighty-five percent of patients improved by one or two NYHA Classes. Survival figures were encouraging with an 11.1% mortality in 12 months and 17.8% mortality in 24 months, comparing favorably with several reports in the literature. There was no positive evidence of toxicity or intolerance in a total of 368.9 patient-years of exposure. Coenzyme Q10 is safe and effective long-term therapy for chronic cardiomyopathy.

Usefulness of Coenzyme Q10 in clinical cardiology: a long-term study

Langsjoen H; Langsjoen P; Langsjoen P; Willis R; Folkers K
University of Texas Medical Branch, Galveston 77551, USA.
Mol Aspects Med (ENGLAND) 1994, 15 Suppl ps165-75

Over an eight-year period (1985-1993), we treated 424 patient with various forms of cardiovascular disease by adding coenzyme Q10 (CoQ10) to their medical regimens. Doses of CoQ10 ranged from 75 to 600 mg/day by mouth (average 242 mg). Treatment was primarily guided by the patient's clinical response. In most instances, CoQ10 levels were employed with the aim of producing a whole blood level greater than or equal to 2.10 micrograms/ml (average 2.92 micrograms/ml, n = 297). Patients were followed for an average of 17.8 months, with a total accumulation of 632 patient years. Eleven patients were omitted from this study: 10 due to noncompliance and one who experienced nausea. Eighteen deaths occurred during the study period with 10 attributable to cardiac causes. Patients were divided into six diagnostic categories: ischemic cardiomyopathy (IMC), dilated cardiomyopathy (DCM), primary diastolic dysfunction (PDD), hypertension (HTN), mitral valve prolapse (MVP), and valvular heart disease (VHD)

For the entire group and for each diagnostic category we evaluated clinical response according to the New York Heart Association (NYHA) functional scale, and found significant improvement of 424 patients, 58 per cent improved by one NYHA class, 28% by two classes and 1.2% by three classes. A statistically significant improvement in myocardial function was documented using the following echo cardiographic parameters: left ventricular wall thickness, mitral valve inflow slope and fractional shortening. Before treatment with CoQ10, most patients were taking from one to five cardiac medications. During this study overall medication requirements dropped considerably: 436 stopped between one and three drugs. Only 6% of the patients required the addition of one drug. No apparent side effects from CoQ10 treatment were noted other than a single case of transient nausea. In conclusion, CoQ10 is a safe and effective adjunctive treatment for a broad range of cardiovascular diseases, producing gratifying clinical responses while easing the medical and financial burden of multi-drug therapy.

Therapy with Coenzyme Q10 of patients in heart failure who are eligible or ineligible for a transplant

Folkers K; Langsjoen H; Langsjoen PH;
lnstitute for Biomedical Research, University of Texas, Austin 78712
Biochem Biophys Res Commun (U.S.)Jan 15 1992 182 (1) p247-53

Twenty years of international open and seven double blind trials established the efficacy and safety of coenzyme Q10 (CoQ10) to treat patients in heart failure. In the US, ca. 44000 patients under 65 years are eligible for transplants, but donors are less than 1/10th of those eligible, and there are many more such patients over 65, both eligible and ineligible. We treated eleven exemplary transplant candidates with CoQ10; all improved; three improved from Class IV to Class I; four improved from Class III-IV to Class II and two improved from Class III to Class I or II. After CoQ10, some patients required no conventional drugs and had no limitation in lifestyle. The marked improvement is based upon correcting myocardial deficiencies of CoQ10 which improve mitochondrial bioenergetics and cardiac performance. These case histories, and very substantial background proof of efficacy and safety, justify treating with CoQ10 patients in failure awaiting transplantation.

Effective and safe therapy with Coenzyme Q10 for cardiomyopathy

Langsjoen PH; Folkers K; Langsjoen H; Lyson K; Muratsu R; Lyson T;
Department of Medicine, Scott & White Clinic, Temple TX.
Klin Wochenschr (GERMANY WEST) Jul 1 1988, 66 (13) p583-90

Coenzyme Q10 (CoQ10) is indispensable in mitochondrial bio energetics and for human life to exist. 88/115 patients completed a trial of therapy with CoQ10 for cardiomyopathy. Patients were selected on the basis of clinical criteria, X-rays electrocardiograms echocardiography and coronary angiography. Responses were monitored by ejection fractions, cardiac output, and improvements in functional classifications (NYHA).

Of the 88 patients 75%-85% showed statistically significant increases in two monitored cardiac parameters. Patients with the lowest jecdon fractions (approx.10%-30%) showed the highest increases (115 delta %-210 delta %) and those with higher ejection fractions (50%-80%) showed increases of approx. 10 delta %-25 delta % on therapy. By functional classification, 17/21 in class IV, 52/62 in class III and 4/5 in class II improved to lower classes. Clinical responses appeared over variable times, and are presumably based on mechanisms of DNA-RNA-protein synthesis of apoenzymes which restore levels of CoQ10 enzymes in a deficiency state. 10/21 (48%) of patients in class IV, 26/62 (42%) in class III, and 2/5 (40%) in class II had exceptionally low control blood levels of CoQ10 . Clinical responses on therapy with CoQ10 appear maximal with blood levels of approx. 2.5 micrograms CoQ10/ml and higher during therapy.

Pronounced increase of survival of patients with cardiomyopathy when treated with Coenzyme Q10 and conventional therapy

Langsjoen PH; Folkers K; Langsjoen H; Lyson K; Muratsu R; Lyson T;
Department of Medicine, Scott & White Clinic, Temple TX.
Int J Tissue React (SWITERZLAND)1990, 12 (3) p163-8

During 1985-86, 43/137 patients with cardiomyopathy, Classes II, III and IV had ejection fractions (EF) below 40%, and a mean EF of 25.1 +/- 10.3%. During treatment of these 43 patients with coenzyme Q10 (CoQ10) EF increased to 41.6 +/- 14.3% (p less than 0.001) over a mean period of 3 months (range, 2-4 months). At four subsequent periods up to 96 months, EF ranged from 43.1 +/- 13.9 to 49.7 +/- 6.4% (each period, p less than 0.001). The mean CoQ10 control blood level was 0.85 +/- 0.26 micrograms/ml which increased on treatment to 1.7 to 2.3 micrograms/ml for five periods up to 36 months (each period, p less than 0.001). The survival rates for all 137 patients treated with CoQ10 and for the 43 patients with EF below 40% were both about 75%/46 months. These two survival rates were comparable between 24 and 46 months, which is of extraordinary significance and importance when compared to survival of about 25%/36 months for 182 patients with EF below 46% on conventional therapy without CoQ10. The improved cardiac function and pronounced increase of survival show that therapy where CoQ10 is remarkably beneficial due to correction of CoQ10 deficiency in mechanisms of bio energetics.

Italian multi-center study on the safety and efficacy of Coenzyme Q10 all as adjunctive therapy in heart failure: when treated with Coenzyme Q10 and conventional therapy CoQ10 Drag Surveillance Investigators

Baggio E; Gandini R; Plancher AC; Passeri M; Carmosino G
Department of Internal Medicine, V. Buzzi Hospital, Reggio Emilia
Mol Aspects Med (ENGLAND) 1994, 15 Suppl ps287-94,

Digitalis, diuretics and vasodilators are considered the standard therapy for patients with congestive heart failure, for which treatment is tailored according to the severity of the syndrome and the patient profile. Apart from the clinical seriousness, heart failure is always characterized by an energy depletion status, as indicated by low intramyocardial ATP and coenzyme Q10 levels. We investigated safety and clinical efficacy of Coenzyme Q10 (CoQ10) adjunctive treatment in congestive heart failure which had been diagnosed at least 6 months previously and treated with standard therapy. A total of 2664 patients in NYHA classes II and III were enrolled in this open noncomparative 3-month post marketing study in 173 Italian centers. The daily dosage of CoQ10 was 50-150 mg orally with the majority of patients (78%) receiving 100 mg/day. Clinical and laboratory parameters were evaluated at the entry into the study and on day 90; the the assessment of clinical signs and symptoms was made using from two to seven-point scales.

The results show a low incidence of side effects: 38 adverse effects were reported in 36 patients (1.5%) of which 22 events were considered as correlated to the test treatment. After three months of test treatment, the proportions of patients with improvement in clinical signs and symptoms were as follows: cyanosis 78.1%, oedema 78.6%, pulmonary rales 77.8%, enlargement of liver area 49.3%, jugular reflux 71.81%, dyspnoea 52.7%, palpitations 75.4%, sweating 79.8%, subjective arrhytmia 63.4%, insomnia 62.8%, vertigo 73.1% and nocturia 53.6%. Moreover we observed a contemporary improvement of at least three symptoms in 54% of patients; this could be interpreted as an index of improved quality of life.

Treatment of occasional hypertension with Coenzyme Q10

Langsjoen PH; Langsjoen PH; Willis R; Folkers K
Institute for Biomedical Research, University of Texas at Austin
Mol Aspects Med (ENGLAND) 1994, 15 Suppl pS265-72

A total of 109 patients with symptomatic essential hypertension presenting to a private cardiology practice were observed after the addition of CoQ10 (average dose, 225 mg/day by mouth) to their existing antihypertensive drug regimen. In 80 per cent of patients, the diagnosis of essential hypertension was established for a year or more prior to starting CoQ10 (average 9.2 years). Only one patient was dropped from analysis due to noncompliance. The dosage of CoQ10 was not fixed and was adjusted according to clinical response and blood CoQ10 levels. Our aim was to attain blood levels greater than 2.0 micrograms/ml (average 3.02 micrograms/ml on CoQ10). Patients were followed closely with frequent clinic visits to record blood pressure and clinical status and make necessary adjustments in drug therapy. Echocardiograms were obtained at baseline in 88% of patients and both at baseline and during treatment in 39% of patients.

A definite and gradual improvement in functional status was observed with the concomitant need to gradually decrease antihypertensive drug therapy within the first one to six months Thereafter, clinical status and cardiovascular drug regimen stabilized with a significantly improved systolic and diastolic blood pressure. Overall New York Heart Association (NYHA) functional class improved from a mean of 2.40 to 166 (P 0.001) and 51% of patients came completely off of between one and three antihypertensive drugs at an average of 4.4 months after starting CoQ10. Only 3% of patients required the addition of one antihypertensive drug. In the 9.4% of patients with echocardiograms both before and during treatment, we observed a highly significant improvement in left ventricular wall thickness and diastolic function.